Category: Sage
-
Scotiabank sees ‘deep value’ in Sage Therapeutics stock despite study setback By Investing.com
•
On Wednesday, Scotiabank revised its outlook on Sage Therapeutics (NASDAQ:SAGE), lowering its price target to $17 from $19 previously while maintaining a sector outperform rating on the stock. The decision comes after the company’s recent stock price decline due to the unsuccessful outcome of the KINETIC-2 study, which tested SAGE-324…
-
DXtrade Teams Up with Sage Capital to Boost Crypto Liquidity for Brokers
•
Payments in Africa: A Cross-Border and Device Revolution | Fmas:24 Payments in Africa: A Cross-Border and Device Revolution | Fmas:24 Payments in Africa: A Cross-Border and Device Revolution | Fmas:24 Payments in Africa: A Cross-Border and Device Revolution | Fmas:24 Payments in Africa: A Cross-Border and Device Revolution | Fmas:24…
-
DXtrade Teams Up with Sage Capital to Boost Crypto Liquidity for Brokers
•
Payments in Africa: A Cross-Border and Device Revolution | Fmas:24 Payments in Africa: A Cross-Border and Device Revolution | Fmas:24 Payments in Africa: A Cross-Border and Device Revolution | Fmas:24 Payments in Africa: A Cross-Border and Device Revolution | Fmas:24 Payments in Africa: A Cross-Border and Device Revolution | Fmas:24…